Free Trial

Travere Therapeutics (TVTX) Financials

Travere Therapeutics logo
$14.91 +0.08 (+0.54%)
Closing price 04/15/2025 04:00 PM Eastern
Extended Trading
$14.93 +0.02 (+0.13%)
As of 04/15/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Travere Therapeutics

Annual Income Statements for Travere Therapeutics

This table shows Travere Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-111 117 -48 -60 -103 -146 -169 -180 -278 -111 -322
Consolidated Net Income / (Loss)
-111 117 -48 -60 -103 -146 -169 -180 -278 -111 -322
Net Income / (Loss) Continuing Operations
-111 117 -48 -60 -103 -146 -169 -217 -331 -376 -321
Total Pre-Tax Income
-113 105 -58 -58 -102 -146 -189 -217 -331 -376 -321
Total Operating Income
-80 -51 -58 -54 -80 -137 -176 -199 -320 -388 -324
Total Gross Profit
28 98 129 151 159 170 192 128 105 134 225
Total Revenue
28 100 134 155 164 175 198 132 109 145 233
Operating Revenue
28 100 134 155 164 175 198 132 109 145 233
Total Cost of Revenue
0.57 2.19 4.55 3.61 5.53 5.23 6.13 3.82 4.42 11 7.74
Operating Cost of Revenue
0.57 2.19 4.55 3.61 5.53 5.23 6.13 3.82 4.42 11 7.74
Total Operating Expenses
107 148 187 205 239 307 368 327 425 522 549
Selling, General & Admin Expense
60 80 92 101 104 129 136 126 198 266 264
Research & Development Expense
48 50 71 78 124 141 229 201 227 245 283
Restructuring Charge
- 0.00 0.89 3.61 -0.24 - - 0.00 0.00 11 2.44
Total Other Income / (Expense), net
-34 156 0.67 -4.57 -22 -9.09 -13 -17 -11 12 3.32
Interest Expense
0.00 4.15 0.73 4.42 27 - 0.00 0.00 19 11 11
Interest & Investment Income
-7.44 -7.75 - 3.23 5.50 -8.77 -14 -18 6.28 22 18
Other Income / (Expense), net
-26 168 1.39 -3.38 -0.47 -0.31 1.42 0.23 0.97 1.59 -3.32
Income Tax Expense
-2.46 -12 -9.68 1.37 0.81 -0.02 -19 0.41 0.31 0.22 0.12
Net Income / (Loss) Discontinued Operations
- - - - - - - 37 53 265 -0.92
Basic Earnings per Share
($4.43) $3.49 ($1.29) ($1.54) ($2.54) ($3.46) ($3.56) ($3.01) ($4.37) ($1.50) ($4.08)
Weighted Average Basic Shares Outstanding
25.06M 33.56M 37.00M 38.77M 40.43M 42.34M 47.54M 59.83M 63.76M 74.27M 78.89M
Diluted Earnings per Share
($4.43) $3.17 ($1.29) ($1.54) ($2.54) ($3.46) ($3.56) ($3.01) ($4.37) ($1.50) ($4.08)
Weighted Average Diluted Shares Outstanding
25.06M 37.58M 38.29M 38.77M 40.43M 42.34M 47.54M 59.83M 63.76M 74.27M 78.89M
Weighted Average Basic & Diluted Shares Outstanding
25.06M 33.60M 37.10M 38.77M 40.43M 42.34M 47.54M 63.21M 64.74M 76.10M 88.74M

Quarterly Income Statements for Travere Therapeutics

This table shows Travere Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-70 -66 -86 -86 151 -90 -136 -70 -54 -61
Consolidated Net Income / (Loss)
-70 -66 -86 -86 151 -90 -136 -70 -55 -60
Net Income / (Loss) Continuing Operations
-84 -104 -97 -102 -89 -89 -136 -70 -55 -60
Total Pre-Tax Income
-84 -104 -96 -102 -89 -89 -136 -70 -55 -60
Total Operating Income
-83 -106 -97 -104 -93 -94 -139 -68 -56 -61
Total Gross Profit
27 -20 27 31 36 40 40 52 61 72
Total Revenue
28 -21 31 32 37 45 41 54 63 75
Operating Revenue
28 -21 31 32 37 45 41 54 63 75
Total Cost of Revenue
1.11 -0.88 4.15 1.45 1.29 4.56 1.50 2.06 1.63 2.55
Operating Cost of Revenue
1.11 -0.88 4.15 1.45 1.29 4.56 1.50 2.06 1.63 2.55
Total Operating Expenses
110 85 124 135 128 135 179 120 117 133
Selling, General & Admin Expense
52 45 66 68 68 64 64 65 66 70
Research & Development Expense
57 54 58 66 61 60 115 54 52 62
Restructuring Charge
- - 0.00 0.00 0.00 11 0.26 0.65 0.12 1.40
Total Other Income / (Expense), net
-1.31 1.29 0.88 2.08 3.36 5.71 3.47 -1.86 1.31 0.40
Interest & Investment Income
-0.73 11 0.80 5.13 5.84 10 3.23 4.42 3.57 6.60
Other Income / (Expense), net
-0.59 0.87 0.09 -0.20 0.34 1.37 0.24 -3.50 0.52 -0.58
Income Tax Expense
0.15 0.06 0.08 0.07 0.01 0.07 0.19 0.09 -0.08 -0.07
Net Income / (Loss) Discontinued Operations
14 - 10 16 240 -1.58 -0.10 -0.76 -0.06 0.00
Basic Earnings per Share
($1.09) ($1.03) ($1.27) ($1.13) $1.97 ($1.07) ($1.76) ($0.91) ($0.70) ($0.71)
Weighted Average Basic Shares Outstanding
64.03M 63.76M 68.17M 76.00M 76.31M 74.27M 77.14M 77.50M 77.78M 78.89M
Diluted Earnings per Share
($1.09) ($1.03) ($1.27) ($1.13) $1.97 ($1.07) ($1.76) ($0.91) ($0.70) ($0.71)
Weighted Average Diluted Shares Outstanding
64.03M 63.76M 68.17M 76.00M 76.31M 74.27M 77.14M 77.50M 77.78M 78.89M
Weighted Average Basic & Diluted Shares Outstanding
64.17M 64.74M 74.61M 75.01M 75.15M 76.10M 76.13M 76.49M 78.05M 88.74M

Annual Cash Flow Statements for Travere Therapeutics

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
12 20 3.20 58 3.48 -40 22 81 -104 -3.51 1.27
Net Cash From Operating Activities
-46 -1.39 -3.44 7.40 -25 -58 -43 -15 -186 -280 -237
Net Cash From Continuing Operating Activities
-46 -1.39 -3.44 7.40 -25 -58 -43 -76 -261 -325 -230
Net Income / (Loss) Continuing Operations
-111 117 -48 -60 -103 -146 -169 -217 -331 -376 -321
Consolidated Net Income / (Loss)
-111 117 -48 -60 -103 -146 -169 -180 -278 -111 -322
Net Income / (Loss) Discontinued Operations
- - - - - - - 37 53 265 -0.92
Depreciation Expense
5.40 13 16 18 19 20 25 13 21 39 44
Amortization Expense
5.79 1.74 1.75 1.99 3.78 9.12 10 13 0.92 -5.74 -2.81
Non-Cash Adjustments To Reconcile Net Income
44 -121 26 31 53 62 130 34 48 44 113
Changes in Operating Assets and Liabilities, net
10 -13 0.93 17 2.53 -3.04 -38 81 0.88 -24 -63
Net Cash From Discontinued Operating Activities
- - - - - - - 61 75 45 -7.45
Net Cash From Investing Activities
-37 -81 10 46 -203 20 -61 -138 -33 56 99
Net Cash From Continuing Investing Activities
-37 -81 10 46 -203 20 -61 -138 -33 -152 99
Acquisitions
-32 -40 -11 -13 -34 -15 -113 -19 -28 -42 -36
Purchase of Investments
-11 -199 -184 -102 -331 -224 -215 -547 -385 -444 -126
Sale and/or Maturity of Investments
6.49 9.98 207 162 163 259 273 434 382 335 326
Other Investing Activities, net
-0.09 0.00 0.00 - - - 0.00 0.00 -0.79 -0.67 -65
Net Cash From Discontinued Investing Activities
- - - - - - - 0.00 0.00 207 0.00
Net Cash From Financing Activities
95 102 -3.85 5.45 232 -2.08 128 232 118 219 139
Net Cash From Continuing Financing Activities
95 102 -3.85 5.45 232 -2.08 128 238 120 220 139
Repayment of Debt
-32 -47 -1.36 -0.85 -41 - 0.00 0.00 -221 0.00 0.00
Issuance of Debt
85 0.00 0.00 0.66 278 - 0.00 0.00 316 0.00 0.00
Issuance of Common Equity
48 154 6.01 3.65 5.31 1.78 134 227 23 219 137
Other Financing Activities, net
-1.16 4.14 -8.50 1.99 -1.13 -3.85 -5.85 11 2.49 3.24 2.35
Net Cash From Discontinued Financing Activities
- - - - - - - -6.10 -2.48 -1.38 0.00
Cash Interest Paid
4.08 5.84 2.07 2.07 1.88 7.67 6.90 7.33 10 8.84 8.84
Cash Income Taxes Paid
0.01 9.61 7.93 7.17 0.22 0.66 -3.37 -16 1.00 0.58 0.45

Quarterly Cash Flow Statements for Travere Therapeutics

This table details how cash moves in and out of Travere Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-28 -90 100 -91 73 -86 -15 -11 4.12 23
Net Cash From Operating Activities
-40 -55 -81 -69 -59 -70 -119 -40 -43 -36
Net Cash From Continuing Operating Activities
-92 -77 -99 -88 -74 -64 -119 -40 -43 -29
Net Income / (Loss) Continuing Operations
-103 -86 -97 -102 -89 -89 -136 -70 -55 -60
Consolidated Net Income / (Loss)
-70 -66 -86 -86 151 -90 -136 -70 -55 -60
Net Income / (Loss) Discontinued Operations
- 20 10 16 240 -1.58 -0.10 -0.76 -0.06 0.00
Depreciation Expense
-0.79 6.31 6.62 11 11 9.49 9.88 10 11 12
Non-Cash Adjustments To Reconcile Net Income
-4.57 6.31 12 9.68 8.23 13 10 80 7.69 15
Changes in Operating Assets and Liabilities, net
17 -5.02 -21 -6.60 -4.90 8.09 -2.95 -61 -6.74 7.40
Net Cash From Discontinued Operating Activities
- 22 18 19 15 -6.10 -0.10 -0.31 0.05 -7.09
Net Cash From Investing Activities
10 -37 -37 -24 133 -17 105 29 46 -80
Net Cash From Continuing Investing Activities
10 -37 -37 -24 -73 -18 105 29 46 -80
Acquisitions
-7.62 -4.17 -27 -3.83 -4.92 -5.51 -6.47 -12 -8.19 -9.64
Purchase of Investments
-95 -84 -103 -122 -156 -63 0.00 - - -126
Sale and/or Maturity of Investments
112 52 94 103 88 50 111 106 54 55
Other Investing Activities, net
- - - - - - - - - -0.04
Net Cash From Financing Activities
2.28 0.55 217 2.27 -0.63 0.12 -0.53 0.78 0.05 139
Net Cash From Continuing Financing Activities
4.15 1.16 218 2.53 -0.37 0.38 -0.53 0.78 0.05 139
Issuance of Common Equity
- 1.45 216 2.26 - 0.91 0.00 1.31 - 136
Other Financing Activities, net
4.15 -0.29 1.77 0.27 -0.37 1.58 -0.53 -0.53 0.05 3.36

Annual Balance Sheets for Travere Therapeutics

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets
135 512 525 520 709 605 607 777 673 789 594
Total Current Assets
37 302 332 326 496 429 410 583 486 617 417
Cash & Equivalents
18 38 41 99 103 62 85 166 62 58 59
Short-Term Investments
9.56 192 215 201 369 336 277 387 389 509 312
Accounts Receivable
7.96 12 19 14 13 18 16 16 17 21 27
Inventories, net
0.80 2.54 2.83 5.35 5.62 6.08 7.61 7.31 4.52 9.41 6.20
Prepaid Expenses
0.81 2.38 4.83 3.11 4.14 5.02 8.14 6.72 12 19 13
Plant, Property, & Equipment, net
0.67 0.43 2.59 3.23 3.15 2.89 9.42 11 9.05 7.48 5.34
Total Noncurrent Assets
97 210 190 191 210 173 188 183 177 165 172
Intangible Assets
94 162 182 185 187 157 154 148 97 104 104
Other Noncurrent Operating Assets
2.27 1.86 7.36 5.56 7.71 15 33 34 32 60 68
Total Liabilities & Shareholders' Equity
135 512 525 520 709 605 607 777 673 789 594
Total Liabilities
173 212 218 227 391 384 396 475 630 588 535
Total Current Liabilities
108 87 83 86 105 95 93 124 142 178 201
Short-Term Debt
40 - - 0.00 22 - 17 7.40 - 0.00 69
Accounts Payable
7.12 7.64 7.52 19 6.95 27 12 15 17 42 24
Accrued Expenses
29 26 35 38 50 52 57 75 96 119 86
Current Deferred Revenue
- - - - - - 0.00 16 12 7.10 2.82
Other Current Liabilities
31 54 40 29 26 17 6.33 10 10 10 20
Total Noncurrent Liabilities
65 125 134 142 286 288 304 350 488 410 334
Long-Term Debt
43 44 44 45 195 205 215 227 376 377 310
Other Noncurrent Operating Liabilities
22 57 83 96 91 83 88 103 37 33 24
Commitments & Contingencies
- - - - - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-37 300 308 293 318 221 211 302 43 201 59
Total Preferred & Common Equity
-37 300 308 293 318 221 211 302 43 201 59
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
-37 300 308 293 318 221 211 302 43 201 59
Common Stock
141 366 421 472 590 637 798 1,069 1,060 1,328 1,506
Retained Earnings
-179 -65 -113 -178 -270 -416 -586 -766 -1,014 -1,126 -1,447
Accumulated Other Comprehensive Income / (Loss)
4.29 -0.68 -0.49 -1.02 -1.53 0.73 -0.90 -0.56 -2.91 -1.46 -0.08

Quarterly Balance Sheets for Travere Therapeutics

This table presents Travere Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
726 808 736 833 664 551 504
Total Current Assets
535 605 542 686 481 369 325
Cash & Equivalents
151 161 71 144 43 32 36
Short-Term Investments
355 400 420 490 398 293 241
Accounts Receivable
13 22 20 15 23 24 25
Inventories, net
7.30 6.71 19 21 4.53 5.98 6.36
Prepaid Expenses
8.55 15 12 16 13 13 16
Plant, Property, & Equipment, net
9.56 9.13 8.57 8.00 6.94 6.58 6.16
Total Noncurrent Assets
182 194 186 139 176 176 174
Intangible Assets
149 163 154 107 101 105 104
Other Noncurrent Operating Assets
32 31 31 32 74 70 69
Total Liabilities & Shareholders' Equity
726 808 736 833 664 551 504
Total Liabilities
626 619 620 553 589 536 535
Total Current Liabilities
131 131 136 139 173 121 190
Short-Term Debt
7.30 6.90 6.90 - - - 69
Accounts Payable
14 17 20 25 17 26 23
Accrued Expenses
88 86 89 96 140 80 84
Current Deferred Revenue
11 11 10 8.96 6.46 5.38 3.80
Other Current Liabilities
9.96 10 9.90 10 10 10 11
Total Noncurrent Liabilities
495 488 484 414 416 415 345
Long-Term Debt
375 376 376 377 378 378 310
Other Noncurrent Operating Liabilities
106 104 101 32 38 37 35
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
101 189 116 280 74 15 -30
Total Preferred & Common Equity
101 189 116 280 74 15 -30
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
101 189 116 280 74 15 -30
Common Stock
1,049 1,292 1,307 1,319 1,338 1,349 1,357
Retained Earnings
-948 -1,101 -1,186 -1,035 -1,262 -1,332 -1,387
Accumulated Other Comprehensive Income / (Loss)
0.30 -2.18 -3.86 -3.65 -1.89 -1.63 -1.02

Annual Metrics and Ratios for Travere Therapeutics

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 254.19% 33.74% 15.98% 6.01% 6.75% 13.11% -33.52% -16.97% 32.69% 60.55%
EBITDA Growth
-176.40% 239.81% -129.39% 4.00% -55.35% -86.26% -29.16% -23.99% -71.59% -19.03% 19.04%
EBIT Growth
-207.11% 210.76% -148.42% -0.62% -40.82% -71.00% -26.92% -13.99% -60.06% -21.23% 15.37%
NOPAT Growth
-222.16% -0.98% 27.76% 7.60% -48.80% -71.62% -28.25% -13.20% -60.37% -21.36% 16.57%
Net Income Growth
-220.40% 205.68% -140.86% -24.69% -71.90% -42.61% -15.71% -6.29% -54.63% 60.00% -188.64%
EPS Growth
-81.56% 171.56% -140.69% -19.38% -64.94% -36.22% -2.89% 15.45% -45.18% 65.68% -172.00%
Operating Cash Flow Growth
-160.67% 96.97% -147.73% 315.14% -437.13% -133.25% 26.58% 65.39% -1,159.40% -50.31% 15.19%
Free Cash Flow Firm Growth
-1,785.20% -51.08% 84.89% 191.93% -421.17% -9.92% -139.36% 77.30% -465.40% -28.96% 4.10%
Invested Capital Growth
172.62% 508.29% -15.61% -60.98% 31.08% -44.11% 199.14% -120.38% 28.64% 193.67% 500.29%
Revenue Q/Q Growth
39.90% 19.59% 5.43% 3.23% 0.98% 1.69% 38.80% -51.60% 18.56% 84.06% 14.61%
EBITDA Q/Q Growth
-0.61% 7.24% 6.77% 4.77% 11.46% -25.34% -176.17% 11.18% -3.67% 2.57% 9.86%
EBIT Q/Q Growth
-8.35% 10.85% 4.65% 2.44% 6.52% -19.77% -106.47% 14.41% -6.82% 2.99% 8.79%
NOPAT Q/Q Growth
-9.53% -2.62% -5.47% 5.36% 11.30% -20.30% -28.66% -9.58% -6.95% 2.85% 9.37%
Net Income Q/Q Growth
-30.99% 29.29% -14.69% -17.78% 9.01% -18.45% -117.03% 28.00% -5.39% -27.97% 8.51%
EPS Q/Q Growth
21.59% 13.21% -98.46% -60.42% 8.63% -17.69% -109.41% 36.63% -5.05% -2.74% 8.11%
Operating Cash Flow Q/Q Growth
-1.55% 79.96% -329.40% 3,236.86% -12.19% -1.62% -28.11% -728.68% -17.51% -5.99% 12.77%
Free Cash Flow Firm Q/Q Growth
-14.20% -26.93% -37.29% 370.47% -16.76% 7.95% -58.59% 18.25% -10.90% 9.22% 5.36%
Invested Capital Q/Q Growth
-46.20% 14.73% 24.20% -17.51% 21.99% -33.35% 42.50% 16.55% 48.43% -48.89% -4.67%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
97.98% 97.81% 96.59% 97.67% 96.63% 97.01% 96.91% 97.10% 95.96% 92.12% 96.68%
EBITDA Margin
-336.03% 132.64% -29.14% -24.12% -35.35% -61.68% -70.43% -131.37% -271.51% -243.57% -122.83%
Operating Margin
-282.98% -50.80% -43.58% -34.72% -48.73% -78.34% -88.83% -151.27% -292.17% -267.24% -138.88%
EBIT Margin
-375.72% 117.49% -42.54% -36.90% -49.02% -78.52% -88.11% -151.09% -291.28% -266.15% -140.30%
Profit (Net Income) Margin
-393.36% 117.36% -35.86% -38.55% -62.51% -83.51% -85.43% -136.60% -254.41% -76.70% -137.90%
Tax Burden Percent
97.83% 111.16% 83.19% 102.34% 100.80% 99.99% 89.75% 83.04% 84.09% 29.62% 100.32%
Interest Burden Percent
107.02% 89.86% 101.34% 102.08% 126.52% 106.37% 108.04% 108.88% 103.86% 97.30% 97.97%
Effective Tax Rate
0.00% -11.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -84.90% -38.73% -56.24% -129.04% -250.42% -224.42% -425.77% 0.00% 0.00% -576.89%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -352.41% -35.13% -46.79% -111.25% -228.69% -195.82% -407.68% 0.00% 0.00% -472.24%
Return on Net Nonoperating Assets (RNNOA)
0.00% 174.14% 22.96% 36.36% 95.45% 196.13% 146.05% 355.60% 0.00% 0.00% 329.44%
Return on Equity (ROE)
389.82% 89.25% -15.76% -19.88% -33.59% -54.29% -78.37% -70.17% -161.46% -91.44% -247.45%
Cash Return on Invested Capital (CROIC)
-535.45% -228.42% -21.79% 31.49% -155.93% -193.83% -324.20% 0.00% 0.00% -2,627.87% -719.77%
Operating Return on Assets (OROA)
-135.88% 36.24% -10.95% -10.94% -13.10% -20.96% -28.83% -28.78% -44.00% -52.90% -47.31%
Return on Assets (ROA)
-142.26% 36.20% -9.23% -11.42% -16.70% -22.29% -27.95% -26.02% -38.43% -15.24% -46.50%
Return on Common Equity (ROCE)
389.82% 89.25% -15.76% -19.88% -33.59% -54.29% -78.37% -70.17% -161.46% -91.44% -247.45%
Return on Equity Simple (ROE_SIMPLE)
297.81% 39.08% -15.56% -20.38% -32.26% -66.20% -80.22% -59.61% -649.88% -55.47% -544.28%
Net Operating Profit after Tax (NOPAT)
-56 -56 -41 -38 -56 -96 -123 -140 -224 -272 -227
NOPAT Margin
-198.08% -56.47% -30.50% -24.30% -34.11% -54.84% -62.18% -105.89% -204.52% -187.07% -97.21%
Net Nonoperating Expense Percent (NNEP)
220.98% 267.51% -3.60% -9.45% -17.79% -21.73% -28.60% -18.09% -29.23% 131.17% -104.65%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - -53.51% -47.00% -51.75%
Cost of Revenue to Revenue
2.02% 2.19% 3.41% 2.33% 3.37% 2.99% 3.09% 2.90% 4.04% 7.88% 3.32%
SG&A Expenses to Revenue
211.48% 79.63% 68.82% 65.40% 63.11% 73.54% 68.47% 95.79% 180.45% 182.83% 113.27%
R&D to Revenue
169.47% 50.48% 53.01% 50.45% 75.35% 80.40% 115.42% 152.58% 207.69% 168.68% 121.24%
Operating Expenses to Revenue
380.95% 148.62% 140.17% 132.39% 145.37% 175.36% 185.74% 248.37% 388.14% 359.36% 235.56%
Earnings before Interest and Taxes (EBIT)
-106 117 -57 -57 -81 -138 -175 -199 -319 -387 -327
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-95 132 -39 -37 -58 -108 -140 -173 -297 -354 -286
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 2.32 2.32 2.83 2.93 2.76 6.59 6.29 31.49 3.36 23.01
Price to Tangible Book Value (P/TBV)
0.00 5.07 5.72 7.71 7.15 9.67 24.37 12.37 0.00 7.01 0.00
Price to Revenue (P/Rev)
11.59 6.98 5.35 5.35 5.68 3.48 7.02 14.42 12.33 4.65 5.83
Price to Earnings (P/E)
0.00 5.95 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 16.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
20.40 4.48 5.22 15.24 13.49 15.12 15.33 0.00 0.00 43.31 20.31
Enterprise Value to Revenue (EV/Rev)
13.57 5.12 3.76 3.70 4.05 2.37 6.37 12.00 11.65 3.35 5.87
Enterprise Value to EBITDA (EV/EBITDA)
0.00 3.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 4.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 77.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 27.16 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-2.25 0.15 0.14 0.15 0.68 0.93 1.10 0.77 8.76 1.88 6.42
Long-Term Debt to Equity
-1.16 0.15 0.14 0.15 0.61 0.93 1.02 0.75 8.76 1.88 5.25
Financial Leverage
-0.88 -0.49 -0.65 -0.78 -0.86 -0.86 -0.75 -0.87 -1.08 -1.00 -0.70
Leverage Ratio
-2.74 2.47 1.71 1.74 2.01 2.44 2.80 2.70 4.20 6.00 5.32
Compound Leverage Factor
-2.93 2.22 1.73 1.78 2.54 2.59 3.03 2.94 4.36 5.84 5.21
Debt to Total Capital
180.07% 12.73% 12.61% 13.33% 40.60% 48.08% 52.42% 43.65% 89.76% 65.26% 86.51%
Short-Term Debt to Total Capital
87.02% 0.00% 0.00% 0.00% 4.19% 0.00% 3.92% 1.38% 0.00% 0.00% 15.68%
Long-Term Debt to Total Capital
93.05% 12.73% 12.61% 13.33% 36.41% 48.08% 48.51% 42.27% 89.76% 65.26% 70.84%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-80.07% 87.27% 87.39% 86.67% 59.40% 51.92% 47.58% 56.35% 10.24% 34.74% 13.49%
Debt to EBITDA
-0.88 0.33 -1.14 -1.21 -3.75 -1.89 -1.67 -1.35 -1.26 -1.07 -1.32
Net Debt to EBITDA
-0.59 -1.40 5.43 6.84 4.63 1.79 0.92 1.84 0.25 0.54 -0.03
Long-Term Debt to EBITDA
-0.46 0.33 -1.14 -1.21 -3.36 -1.89 -1.54 -1.31 -1.26 -1.07 -1.08
Debt to NOPAT
-1.50 -0.78 -1.09 -1.20 -3.88 -2.13 -1.89 -1.68 -1.68 -1.39 -1.67
Net Debt to NOPAT
-1.00 3.29 5.19 6.79 4.80 2.01 1.04 2.28 0.33 0.70 -0.04
Long-Term Debt to NOPAT
-0.77 -0.78 -1.09 -1.20 -3.48 -2.13 -1.75 -1.62 -1.68 -1.39 -1.37
Altman Z-Score
-3.71 3.25 2.14 2.20 1.42 0.19 0.76 1.05 -1.61 -2.07 -2.87
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
0.35 3.47 3.99 3.80 4.74 4.50 4.43 4.70 3.42 3.47 2.08
Quick Ratio
0.33 3.32 3.86 3.67 4.63 4.36 4.07 4.58 3.28 3.31 1.98
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-100 -152 -23 21 -68 -74 -178 -40 -229 -295 -283
Operating Cash Flow to CapEx
-6,915.54% 0.00% -240.97% 834.61% -3,433.01% -29,853.33% -631.64% -289.98% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -36.57 -31.63 4.77 -2.52 0.00 0.00 0.00 -12.30 -26.02 -25.29
Operating Cash Flow to Interest Expense
0.00 -0.33 -4.75 1.67 -0.93 0.00 0.00 0.00 -10.02 -24.71 -21.24
Operating Cash Flow Less CapEx to Interest Expense
0.00 35.41 -6.72 1.47 -0.96 0.00 0.00 0.00 -10.02 -24.71 -21.24
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.36 0.31 0.26 0.30 0.27 0.27 0.33 0.19 0.15 0.20 0.34
Accounts Receivable Turnover
0.00 9.78 8.63 9.57 12.38 11.42 11.68 8.28 6.72 7.68 9.66
Inventory Turnover
0.00 1.31 1.70 0.88 1.01 0.89 0.90 0.51 0.75 1.64 0.99
Fixed Asset Turnover
70.65 181.79 88.62 53.27 51.52 58.09 32.22 12.85 10.86 17.57 36.39
Accounts Payable Turnover
0.11 0.30 0.60 0.27 0.43 0.31 0.32 0.28 0.27 0.39 0.24
Days Sales Outstanding (DSO)
0.00 37.30 42.31 38.14 29.48 31.96 31.26 44.07 54.29 47.53 37.80
Days Inventory Outstanding (DIO)
0.00 278.72 214.88 413.95 362.23 407.99 407.84 713.22 488.70 222.08 367.88
Days Payable Outstanding (DPO)
3,412.71 1,233.07 607.57 1,339.51 854.95 1,170.45 1,154.31 1,303.84 1,339.19 939.84 1,536.76
Cash Conversion Cycle (CCC)
-3,412.71 -917.04 -350.39 -887.42 -463.24 -730.50 -715.21 -546.54 -796.20 -670.23 -1,131.08
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
19 114 96 38 49 28 82 -17 -12 11 67
Invested Capital Turnover
-7.97 1.50 1.27 2.31 3.78 4.57 3.61 4.02 -7.61 -382.71 5.93
Increase / (Decrease) in Invested Capital
45 95 -18 -59 12 -22 55 -99 4.81 23 56
Enterprise Value (EV)
383 511 503 573 664 416 1,263 1,582 1,275 486 1,368
Market Capitalization
327 697 714 828 933 610 1,391 1,900 1,350 676 1,360
Book Value per Share
($1.40) $8.30 $8.16 $7.46 $7.72 $5.15 $4.14 $4.93 $0.67 $2.67 $0.76
Tangible Book Value per Share
($4.96) $3.80 $3.31 $2.73 $3.17 $1.47 $1.12 $2.51 ($0.84) $1.28 ($0.58)
Total Capital
47 344 352 338 536 426 444 536 418 578 438
Total Debt
84 44 44 45 218 205 233 234 376 377 379
Total Long-Term Debt
43 44 44 45 195 205 215 227 376 377 310
Net Debt
56 -186 -211 -256 -269 -194 -129 -319 -75 -190 8.29
Capital Expenditures (CapEx)
0.66 -148 1.43 0.89 0.73 0.20 6.77 5.10 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-57 -15 -6.78 -60 -58 -65 -26 -87 -106 -128 -86
Debt-free Net Working Capital (DFNWC)
-30 215 249 240 414 334 335 466 344 439 285
Net Working Capital (NWC)
-70 215 249 240 391 334 318 459 344 439 216
Net Nonoperating Expense (NNE)
55 -174 7.15 22 47 50 46 40 55 -160 95
Net Nonoperating Obligations (NNO)
56 -186 -211 -256 -269 -194 -129 -319 -55 -190 8.29
Total Depreciation and Amortization (D&A)
11 15 18 20 22 30 35 26 22 33 41
Debt-free, Cash-free Net Working Capital to Revenue
-203.80% -14.67% -5.08% -39.04% -35.33% -37.02% -13.33% -65.80% -96.81% -88.12% -36.91%
Debt-free Net Working Capital to Revenue
-105.38% 215.18% 186.46% 154.99% 251.77% 190.27% 168.99% 353.57% 314.52% 302.17% 122.07%
Net Working Capital to Revenue
-248.93% 215.18% 186.46% 154.99% 238.09% 190.27% 160.22% 347.96% 314.52% 302.17% 92.61%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($4.43) $3.49 ($1.29) ($1.54) ($2.54) ($3.46) ($3.56) ($3.01) ($4.37) ($1.50) ($4.08)
Adjusted Weighted Average Basic Shares Outstanding
26.49M 33.56M 37.00M 38.77M 40.43M 43.12M 60.24M 59.83M 63.76M 74.27M 78.89M
Adjusted Diluted Earnings per Share
($4.43) $3.17 ($1.29) ($1.54) ($2.54) ($3.46) ($3.56) ($3.01) ($4.37) ($1.50) ($4.08)
Adjusted Weighted Average Diluted Shares Outstanding
26.49M 37.58M 38.29M 38.77M 40.43M 43.12M 60.24M 59.83M 63.76M 74.27M 78.89M
Adjusted Basic & Diluted Earnings per Share
($4.43) $0.00 $0.00 $0.00 ($2.54) ($3.46) ($3.56) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.06M 36.51M 38.09M 39.69M 41.41M 42.34M 47.54M 63.21M 64.74M 76.10M 88.74M
Normalized Net Operating Profit after Tax (NOPAT)
-56 -23 -24 -33 -56 -68 -123 -140 -224 -264 -225
Normalized NOPAT Margin
-198.08% -22.61% -17.67% -21.49% -34.22% -38.67% -62.18% -105.89% -204.52% -181.58% -96.48%
Pre Tax Income Margin
-402.08% 105.58% -43.10% -37.67% -62.02% -83.52% -95.19% -164.51% -302.54% -258.96% -137.45%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 28.27 -78.38 -12.93 -3.00 0.00 0.00 0.00 -17.15 -34.10 -29.26
NOPAT to Interest Expense
0.00 -13.59 -56.21 -8.52 -2.09 0.00 0.00 0.00 -12.04 -23.97 -20.27
EBIT Less CapEx to Interest Expense
0.00 64.02 -80.35 -13.13 -3.03 0.00 0.00 0.00 -17.15 -34.10 -29.26
NOPAT Less CapEx to Interest Expense
0.00 22.16 -58.18 -8.72 -2.11 0.00 0.00 0.00 -12.04 -23.97 -20.27
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-4.89% 8.10% 0.00% 0.00% -8.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Travere Therapeutics

This table displays calculated financial ratios and metrics derived from Travere Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
-58.84% 44.62% -36.30% -40.56% 32.13% 311.85% 33.95% 68.08% 69.56% 65.98%
EBITDA Growth
-315.50% -12.05% -53.63% -64.44% 4.47% 14.79% -42.42% 34.71% 45.04% 40.96%
EBIT Growth
-167.86% -24.12% -47.17% -60.76% -10.89% 11.36% -42.88% 31.64% 39.70% 33.97%
NOPAT Growth
-160.49% -24.49% -47.24% -58.82% -12.08% 10.79% -43.00% 34.87% 39.35% 35.55%
Net Income Growth
-95.45% -27.63% -13.64% -27.75% 316.40% -36.99% -57.60% 17.78% -136.36% 33.17%
EPS Growth
-84.75% -25.61% -5.83% -7.62% 280.73% -3.88% -38.58% 19.47% -135.53% 33.64%
Operating Cash Flow Growth
-223.27% -103.30% -46.63% -88.28% -49.61% -28.98% -46.71% 41.93% 28.12% 49.31%
Free Cash Flow Firm Growth
-198.19% -298.07% -440.78% -9,747.35% -101.07% -13.23% -6.09% -11.63% 19.99% -10.65%
Invested Capital Growth
-15.48% 28.64% 178.27% 158.40% 194.50% 193.67% 2.09% 703.17% 221.84% 500.29%
Revenue Q/Q Growth
-48.17% -175.76% 245.23% 4.23% 15.22% 21.47% -8.18% 30.80% 16.23% 18.90%
EBITDA Q/Q Growth
-49.18% -15.72% 7.34% -2.80% 13.34% -3.22% -53.84% 52.87% 27.05% -10.90%
EBIT Q/Q Growth
-28.40% -25.92% 7.13% -7.06% 11.43% -0.66% -49.69% 48.78% 21.87% -10.23%
NOPAT Q/Q Growth
-26.21% -27.87% 7.82% -6.76% 10.93% -1.78% -47.76% 51.38% 17.07% -8.17%
Net Income Q/Q Growth
-3.91% 5.50% -31.16% 0.81% 276.03% -159.82% -50.89% 48.25% 22.15% -9.95%
EPS Q/Q Growth
-3.81% 5.50% -23.30% 11.02% 274.34% -154.31% -64.49% 48.30% 23.08% -1.43%
Operating Cash Flow Q/Q Growth
-7.39% -38.24% -48.46% 14.57% 14.67% -19.18% -68.87% 66.18% -5.63% 15.97%
Free Cash Flow Firm Q/Q Growth
-5,530.11% -43.94% -16.92% -3.92% -14.96% 18.94% -9.55% -9.35% 17.61% -12.10%
Invested Capital Q/Q Growth
-60.56% 48.43% 187.65% -19.52% 159.80% -48.89% -4.47% 533.17% 4.11% -4.67%
Profitability Metrics
- - - - - - - - - -
Gross Margin
96.03% 0.00% 86.58% 95.49% 96.53% 89.87% 96.36% 96.19% 97.41% 96.59%
EBITDA Margin
-301.18% 0.00% -293.52% -289.49% -217.75% -185.03% -312.08% -112.45% -70.57% -65.82%
Operating Margin
-294.23% 0.00% -315.23% -322.87% -249.59% -209.13% -336.53% -125.11% -89.27% -81.21%
EBIT Margin
-296.31% 0.00% -314.95% -323.49% -248.69% -206.09% -335.96% -131.57% -88.44% -81.99%
Profit (Net Income) Margin
-248.11% 0.00% -279.50% -265.96% 406.35% -200.12% -328.86% -130.11% -87.14% -80.58%
Tax Burden Percent
83.00% 63.09% 89.48% 84.06% -168.93% 101.86% 100.22% 101.21% 99.95% 99.87%
Interest Burden Percent
100.88% 99.60% 99.18% 97.81% 96.73% 95.33% 97.67% 97.71% 98.57% 98.41%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,457.36% -407.65% -274.53% -337.36%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,425.46% -324.42% -254.73% -317.78%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3,149.29% 136.30% 160.10% 221.69%
Return on Equity (ROE)
-129.51% -161.46% -145.41% -225.07% -45.76% -91.44% -308.07% -271.35% -114.43% -115.67%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -2,567.88% -3,497.90% -1,479.61% -2,627.87% -2,838.92% -877.95% -645.30% -719.77%
Operating Return on Assets (OROA)
-36.44% 0.00% -35.36% -29.83% -25.17% -40.96% -71.09% -36.30% -26.91% -27.65%
Return on Assets (ROA)
-30.52% 0.00% -31.38% -24.52% 41.13% -39.77% -69.59% -35.90% -26.52% -27.17%
Return on Common Equity (ROCE)
-129.51% -161.46% -145.41% -225.07% -45.76% -91.44% -308.07% -271.35% -114.43% -115.67%
Return on Equity Simple (ROE_SIMPLE)
-262.46% 0.00% -152.71% -263.93% -31.11% 0.00% -217.53% -963.28% 1,154.05% 0.00%
Net Operating Profit after Tax (NOPAT)
-58 -74 -68 -73 -65 -66 -97 -47 -39 -43
NOPAT Margin
-205.96% 0.00% -220.66% -226.01% -174.71% -146.39% -235.57% -87.58% -62.49% -56.85%
Net Nonoperating Expense Percent (NNEP)
-5.24% 4.34% -9.08% -9.21% 112.93% -19.81% -31.90% -83.23% -19.79% -19.58%
Return On Investment Capital (ROIC_SIMPLE)
- -17.67% - - - -11.41% - - - -9.71%
Cost of Revenue to Revenue
3.97% 0.00% 13.42% 4.51% 3.47% 10.13% 3.64% 3.81% 2.59% 3.41%
SG&A Expenses to Revenue
186.71% 0.00% 213.51% 211.84% 182.78% 141.12% 155.23% 119.70% 104.33% 92.93%
R&D to Revenue
203.54% 0.00% 188.30% 206.52% 163.34% 132.60% 277.05% 100.40% 82.16% 82.99%
Operating Expenses to Revenue
390.26% 0.00% 401.81% 418.36% 346.11% 299.00% 432.90% 221.30% 186.68% 177.80%
Earnings before Interest and Taxes (EBIT)
-83 -105 -97 -104 -92 -93 -139 -71 -56 -61
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-85 -98 -91 -93 -81 -83 -129 -61 -44 -49
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
15.65 31.49 7.70 9.84 2.40 3.36 7.82 41.31 0.00 23.01
Price to Tangible Book Value (P/TBV)
0.00 0.00 55.46 0.00 3.88 7.01 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
17.07 12.33 15.85 16.40 8.50 4.65 3.72 3.52 5.26 5.83
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 121.65 122.82 18.80 43.31 48.14 10.00 16.57 20.31
Enterprise Value to Revenue (EV/Rev)
15.73 11.65 13.91 14.85 5.23 3.35 3.31 3.82 5.76 5.87
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
3.80 8.76 2.02 3.29 1.35 1.88 5.10 24.96 -12.43 6.42
Long-Term Debt to Equity
3.73 8.76 1.99 3.23 1.35 1.88 5.10 24.96 -10.18 5.25
Financial Leverage
-1.11 -1.08 -1.01 -1.02 -1.00 -1.00 -0.92 -0.42 -0.63 -0.70
Leverage Ratio
3.68 4.20 4.12 5.55 4.10 6.00 5.59 9.78 5.36 5.32
Compound Leverage Factor
3.71 4.18 4.09 5.43 3.96 5.72 5.46 9.56 5.29 5.24
Debt to Total Capital
79.16% 89.76% 66.93% 76.69% 57.39% 65.26% 83.60% 96.15% 108.75% 86.51%
Short-Term Debt to Total Capital
1.51% 0.00% 1.21% 1.38% 0.00% 0.00% 0.00% 0.00% 19.71% 15.68%
Long-Term Debt to Total Capital
77.65% 89.76% 65.73% 75.31% 57.39% 65.26% 83.60% 96.15% 89.04% 70.84%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
20.84% 10.24% 33.07% 23.31% 42.61% 34.74% 16.40% 3.85% -8.75% 13.49%
Debt to EBITDA
-1.33 -1.26 -1.16 -1.05 -1.04 -1.07 -0.98 -1.07 -1.19 -1.32
Net Debt to EBITDA
0.43 0.25 0.54 0.29 0.71 0.54 0.16 -0.15 -0.32 -0.03
Long-Term Debt to EBITDA
-1.31 -1.26 -1.14 -1.03 -1.04 -1.07 -0.98 -1.07 -0.98 -1.08
Debt to NOPAT
-1.83 -1.68 -1.56 -1.41 -1.35 -1.39 -1.25 -1.37 -1.51 -1.67
Net Debt to NOPAT
0.59 0.33 0.73 0.40 0.92 0.70 0.21 -0.19 -0.40 -0.04
Long-Term Debt to NOPAT
-1.79 -1.68 -1.53 -1.38 -1.35 -1.39 -1.25 -1.37 -1.24 -1.37
Altman Z-Score
0.10 -0.56 -0.07 -0.86 -0.50 -0.85 -1.97 -2.25 -2.29 -1.40
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
4.08 3.42 4.63 3.99 4.92 3.47 2.78 3.04 1.71 2.08
Quick Ratio
3.96 3.28 4.46 3.77 4.66 3.31 2.68 2.89 1.59 1.98
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-55 -79 -92 -96 -110 -89 -98 -107 -88 -99
Operating Cash Flow to CapEx
0.00% 0.00% -12,875.71% -2,309,900.00% -591,340.00% 0.00% 0.00% -49,076.83% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 -7.15 0.00 -33.66 -38.99 0.00 0.00 -38.31 -31.69 0.00
Operating Cash Flow to Interest Expense
0.00 -4.96 0.00 -24.37 -20.96 0.00 0.00 -14.43 -15.31 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 -4.96 0.00 -24.38 -20.97 0.00 0.00 -14.46 -15.31 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.12 0.15 0.11 0.09 0.10 0.20 0.21 0.28 0.30 0.34
Accounts Receivable Turnover
7.09 6.72 5.07 3.77 5.79 7.68 7.04 7.92 10.24 9.66
Inventory Turnover
0.61 0.75 0.97 0.44 0.43 1.64 1.57 0.76 0.72 0.99
Fixed Asset Turnover
8.76 10.86 9.31 7.49 8.99 17.57 19.38 23.45 28.74 36.39
Accounts Payable Turnover
0.43 0.27 0.37 0.37 0.31 0.39 0.53 0.41 0.41 0.24
Days Sales Outstanding (DSO)
51.47 54.29 71.94 96.84 63.00 47.53 51.88 46.09 35.65 37.80
Days Inventory Outstanding (DIO)
599.84 488.70 375.76 826.60 853.37 222.08 232.95 479.43 507.54 367.88
Days Payable Outstanding (DPO)
855.37 1,339.19 998.43 994.64 1,177.94 939.84 693.04 886.69 896.71 1,536.76
Cash Conversion Cycle (CCC)
-204.06 -796.20 -550.72 -71.19 -261.57 -670.23 -408.21 -361.17 -353.52 -1,131.08
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-23 -12 11 8.45 22 11 11 68 71 67
Invested Capital Turnover
-4.26 -7.61 -63.03 -23.22 -123.59 -382.71 14.68 4.65 4.39 5.93
Increase / (Decrease) in Invested Capital
-3.12 4.81 24 23 45 23 0.22 59 49 56
Enterprise Value (EV)
1,452 1,275 1,277 1,038 413 486 516 679 1,171 1,368
Market Capitalization
1,576 1,350 1,456 1,146 671 676 579 626 1,070 1,360
Book Value per Share
$1.57 $0.67 $2.92 $1.56 $3.73 $2.67 $0.96 $0.20 ($0.40) $0.76
Tangible Book Value per Share
($0.76) ($0.84) $0.41 ($0.51) $2.30 $1.28 ($0.35) ($1.18) ($1.76) ($0.58)
Total Capital
483 418 572 500 657 578 452 393 348 438
Total Debt
382 376 383 383 377 377 378 378 379 379
Total Long-Term Debt
375 376 376 376 377 377 378 378 310 310
Net Debt
-124 -75 -179 -108 -258 -190 -63 53 101 8.29
Capital Expenditures (CapEx)
0.00 0.00 0.63 0.00 0.01 0.00 0.00 0.08 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-95 -106 -80 -78 -88 -128 -133 -78 -74 -86
Debt-free Net Working Capital (DFNWC)
411 344 481 413 547 439 308 248 203 285
Net Working Capital (NWC)
404 344 474 406 547 439 308 248 135 216
Net Nonoperating Expense (NNE)
12 -8.12 18 13 -216 24 39 23 16 18
Net Nonoperating Obligations (NNO)
-124 -55 -179 -108 -258 -190 -63 53 101 8.29
Total Depreciation and Amortization (D&A)
-1.37 6.91 6.62 11 11 9.49 9.88 10 11 12
Debt-free, Cash-free Net Working Capital to Revenue
-103.13% -96.81% -87.47% -111.74% -111.32% -88.12% -85.53% -43.73% -36.44% -36.91%
Debt-free Net Working Capital to Revenue
445.29% 314.52% 523.79% 591.28% 692.94% 302.17% 197.69% 139.44% 99.93% 122.07%
Net Working Capital to Revenue
437.38% 314.52% 516.28% 581.41% 692.94% 302.17% 197.69% 139.44% 66.21% 92.61%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($1.09) ($1.03) ($1.27) ($1.13) $1.97 ($1.07) ($1.76) ($0.91) ($0.70) ($0.71)
Adjusted Weighted Average Basic Shares Outstanding
64.03M 63.76M 68.17M 76.00M 76.31M 74.27M 77.14M 77.50M 77.78M 78.89M
Adjusted Diluted Earnings per Share
($1.09) ($1.03) ($1.27) ($1.13) $1.97 ($1.07) ($1.76) ($0.91) ($0.70) ($0.71)
Adjusted Weighted Average Diluted Shares Outstanding
64.03M 63.76M 68.17M 76.00M 76.31M 74.27M 77.14M 77.50M 77.78M 78.89M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
64.17M 64.74M 74.61M 75.01M 75.15M 76.10M 76.13M 76.49M 78.05M 88.74M
Normalized Net Operating Profit after Tax (NOPAT)
-58 -74 -68 -73 -65 -58 -97 -47 -39 -42
Normalized NOPAT Margin
-205.96% 0.00% -220.66% -226.01% -174.71% -128.69% -235.13% -86.73% -62.35% -55.54%
Pre Tax Income Margin
-298.91% 0.00% -312.37% -316.40% -240.54% -196.47% -328.15% -128.55% -87.18% -80.68%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 -9.51 0.00 -36.63 -32.70 0.00 0.00 -25.54 -20.03 0.00
NOPAT to Interest Expense
0.00 -6.71 0.00 -25.59 -22.97 0.00 0.00 -17.00 -14.15 0.00
EBIT Less CapEx to Interest Expense
0.00 -9.51 0.00 -36.64 -32.70 0.00 0.00 -25.57 -20.03 0.00
NOPAT Less CapEx to Interest Expense
0.00 -6.71 0.00 -25.60 -22.98 0.00 0.00 -17.03 -14.15 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Travere Therapeutics' Financials

When does Travere Therapeutics's financial year end?

According to the most recent income statement we have on file, Travere Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Travere Therapeutics' net income changed over the last 10 years?

Travere Therapeutics' net income appears to be on an upward trend, with a most recent value of -$321.55 million in 2024, rising from -$110.94 million in 2014. The previous period was -$111.40 million in 2023.

What is Travere Therapeutics's operating income?
Travere Therapeutics's total operating income in 2024 was -$323.83 million, based on the following breakdown:
  • Total Gross Profit: $225.43 million
  • Total Operating Expenses: $549.26 million
How has Travere Therapeutics revenue changed over the last 10 years?

Over the last 10 years, Travere Therapeutics' total revenue changed from $28.20 million in 2014 to $233.18 million in 2024, a change of 726.8%.

How much debt does Travere Therapeutics have?

Travere Therapeutics' total liabilities were at $535.05 million at the end of 2024, a 9.0% decrease from 2023, and a 209.8% increase since 2014.

How much cash does Travere Therapeutics have?

In the past 10 years, Travere Therapeutics' cash and equivalents has ranged from $18.20 million in 2014 to $165.75 million in 2021, and is currently $58.54 million as of their latest financial filing in 2024.

How has Travere Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Travere Therapeutics' book value per share changed from -1.40 in 2014 to 0.76 in 2024, a change of -154.3%.

Remove Ads


This page (NASDAQ:TVTX) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners